The scientists received backing in the form of a €2.4 million EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.
The test does not require thermal cycling and uses a colorimetric readout, making it more amenable to high-throughput automation and rapid scale-up, the company said.
Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.
